Yiran Zhang, Zhikang Xiao, Zhe Fan, Yingxin Zhang, Jianzhong Xu, Kun Wang
{"title":"The impact of platelet-rich plasma injection on anterior cruciate ligament reconstruction: a systematic review and meta-analysis.","authors":"Yiran Zhang, Zhikang Xiao, Zhe Fan, Yingxin Zhang, Jianzhong Xu, Kun Wang","doi":"10.3389/fbioe.2025.1625271","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review and meta-analysis evaluates platelet-rich plasma (PRP) efficacy in anterior cruciate ligament reconstruction (ACLR) through 15-year Randomized controlled trials (RCTs) data, focusing on postoperative recovery, rehabilitation acceleration, and functional outcomes optimization.</p><p><strong>Methods: </strong>We conducted an extensive systematic search in PubMed, Embase, and Web of Science to find relevant studies on using PRP in ACLR. Randomized controlled trials analyzing the comparative effectiveness of PRP compared to control interventions in individuals undergoing ACLR were systematically identified. The focus was on studies that provided reliable outcome measures, encompassing validated clinical assessments and objective imaging results. Outcome indicators included the Visual Analog Scale (VAS) for pain perception, the International Knee Documentation Committee (IKDC) score, Lysholm score, Tegner activity scale, KT-1000 side-to-side difference, graft characteristics, and associated complications. Additionally, subgroup analyses were categorized based on evaluation timelines, distinguishing between preoperative and postoperative assessments.</p><p><strong>Results: </strong>This meta-analysis of 24 studies demonstrated time-dependent effects of PRP supplementation following ACLR. The PRP group exhibited significant improvement in IKDC scores at 12 months post-operatively (mean difference: 2.09, P = 0.01, I<sup>2</sup> = 23%), while Lysholm scores showed significant enhancement at 6 months (mean difference: 3.33, P = 0.03, I<sup>2</sup> = 58%). Pain reduction, assessed by VAS scores, was significantly greater in the PRP group at 3 months (mean difference: -1.33, P < 0.01, I<sup>2</sup> = 38%) with borderline significance at 6 months (mean difference: -0.78, P = 0.05). Notably, PRP intervention significantly reduced anterior tibial translation compared to controls (mean difference: -1.34 mm, 95% CI: -1.56 to -1.13, P < 0.01, I<sup>2</sup> = 73%), indicating improved knee stability. Pre-operative KT-1000 measurements suggested a trend toward reduced knee laxity in the PRP group (mean difference: -0.70 mm, 95% CI: -1.45 to 0.05, P = 0.07), though this effect did not persist post-operatively. No significant between-group differences were observed in Tegner activity scores, Signal-to-Noise Quotient, or Pivot Shift Test results at any follow-up interval.</p><p><strong>Conclusion: </strong>This meta-analysis indicates that PRP application during and shortly after ACLR offers limited clinical benefits. Although there is notable short-term pain relief, long-term efficacy remains unclear, with improvements not meeting minimal clinically important differences (MCID) and no significant changes in knee stability or graft maturation. Further research is needed to establish optimal PRP protocols and standardization for ACLR.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1625271"},"PeriodicalIF":4.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12521423/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1625271","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This systematic review and meta-analysis evaluates platelet-rich plasma (PRP) efficacy in anterior cruciate ligament reconstruction (ACLR) through 15-year Randomized controlled trials (RCTs) data, focusing on postoperative recovery, rehabilitation acceleration, and functional outcomes optimization.
Methods: We conducted an extensive systematic search in PubMed, Embase, and Web of Science to find relevant studies on using PRP in ACLR. Randomized controlled trials analyzing the comparative effectiveness of PRP compared to control interventions in individuals undergoing ACLR were systematically identified. The focus was on studies that provided reliable outcome measures, encompassing validated clinical assessments and objective imaging results. Outcome indicators included the Visual Analog Scale (VAS) for pain perception, the International Knee Documentation Committee (IKDC) score, Lysholm score, Tegner activity scale, KT-1000 side-to-side difference, graft characteristics, and associated complications. Additionally, subgroup analyses were categorized based on evaluation timelines, distinguishing between preoperative and postoperative assessments.
Results: This meta-analysis of 24 studies demonstrated time-dependent effects of PRP supplementation following ACLR. The PRP group exhibited significant improvement in IKDC scores at 12 months post-operatively (mean difference: 2.09, P = 0.01, I2 = 23%), while Lysholm scores showed significant enhancement at 6 months (mean difference: 3.33, P = 0.03, I2 = 58%). Pain reduction, assessed by VAS scores, was significantly greater in the PRP group at 3 months (mean difference: -1.33, P < 0.01, I2 = 38%) with borderline significance at 6 months (mean difference: -0.78, P = 0.05). Notably, PRP intervention significantly reduced anterior tibial translation compared to controls (mean difference: -1.34 mm, 95% CI: -1.56 to -1.13, P < 0.01, I2 = 73%), indicating improved knee stability. Pre-operative KT-1000 measurements suggested a trend toward reduced knee laxity in the PRP group (mean difference: -0.70 mm, 95% CI: -1.45 to 0.05, P = 0.07), though this effect did not persist post-operatively. No significant between-group differences were observed in Tegner activity scores, Signal-to-Noise Quotient, or Pivot Shift Test results at any follow-up interval.
Conclusion: This meta-analysis indicates that PRP application during and shortly after ACLR offers limited clinical benefits. Although there is notable short-term pain relief, long-term efficacy remains unclear, with improvements not meeting minimal clinically important differences (MCID) and no significant changes in knee stability or graft maturation. Further research is needed to establish optimal PRP protocols and standardization for ACLR.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.